1. Home
  2. RNAZ vs IPDN Comparison

RNAZ vs IPDN Comparison

Compare RNAZ & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • IPDN
  • Stock Information
  • Founded
  • RNAZ 2016
  • IPDN 2003
  • Country
  • RNAZ United States
  • IPDN United States
  • Employees
  • RNAZ N/A
  • IPDN N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • IPDN EDP Services
  • Sector
  • RNAZ Health Care
  • IPDN Technology
  • Exchange
  • RNAZ Nasdaq
  • IPDN Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • IPDN 5.4M
  • IPO Year
  • RNAZ 2021
  • IPDN 2013
  • Fundamental
  • Price
  • RNAZ $11.51
  • IPDN $2.24
  • Analyst Decision
  • RNAZ Strong Buy
  • IPDN
  • Analyst Count
  • RNAZ 1
  • IPDN 0
  • Target Price
  • RNAZ $280.00
  • IPDN N/A
  • AVG Volume (30 Days)
  • RNAZ 251.6K
  • IPDN 2.1M
  • Earning Date
  • RNAZ 08-22-2025
  • IPDN 08-19-2025
  • Dividend Yield
  • RNAZ N/A
  • IPDN N/A
  • EPS Growth
  • RNAZ N/A
  • IPDN N/A
  • EPS
  • RNAZ N/A
  • IPDN N/A
  • Revenue
  • RNAZ N/A
  • IPDN $6,508,349.00
  • Revenue This Year
  • RNAZ N/A
  • IPDN N/A
  • Revenue Next Year
  • RNAZ N/A
  • IPDN N/A
  • P/E Ratio
  • RNAZ N/A
  • IPDN N/A
  • Revenue Growth
  • RNAZ N/A
  • IPDN N/A
  • 52 Week Low
  • RNAZ $6.15
  • IPDN $0.97
  • 52 Week High
  • RNAZ $739.20
  • IPDN $11.20
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 56.95
  • IPDN 50.94
  • Support Level
  • RNAZ $10.16
  • IPDN $2.42
  • Resistance Level
  • RNAZ $12.10
  • IPDN $2.68
  • Average True Range (ATR)
  • RNAZ 1.40
  • IPDN 0.23
  • MACD
  • RNAZ -0.11
  • IPDN -0.03
  • Stochastic Oscillator
  • RNAZ 23.51
  • IPDN 43.09

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About IPDN Professional Diversity Network Inc.

Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates majority of its revenue from TalentAlly Network Segment.

Share on Social Networks: